There are 3163 resources available
EU HTA Regulation: State of play for cancer medicines
Presenter: Maya Matthews
Session: ESMO-MCBS: A practical tool with public health implications
Resources:
Slides
Webcast
1959O - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)
Presenter: Dingwei Ye
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
443O - A perioperative study of safusidenib in patients with IDH1 mutated glioma
Presenter: James Whittle
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
803MO - CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis
Presenter: Myriam BEN KHELIL
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA81 and 1786MO
Presenter: Stephen Liu
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Slides
Webcast
Q&A and discussion
Session: Why neoadjuvant immunotherapy is the future for melanoma
Resources:
Webcast
Discussion
Session: Beyond coding neoantigens: What else is there for T cells to see?
Resources:
Webcast
Q&A and discussion
Session: New endpoints in early clinical trials
Resources:
Webcast
Conclusions and perspectives
Presenter: Nathan Cherny
Session: ESMO-MCBS: A practical tool with public health implications
Resources:
Webcast
1690O - NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Presenter: Eric Jonasch
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast